SUBSCRIBE
SUBSCRIBE
News   Drug Development

New Octapharma AG 10% High Purity Immunoglobulin Enters Phase II/III Study in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

September 8, 2010 | 
1 min read
LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Clinical research Phase II Europe
MORE ON THIS TOPIC
Map with different syringes. Covid 19 and pandemic vaccination concept. Vector illustration
Earnings
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots
October 24, 2025
 · 
2 min read
 · 
Annalee Armstrong
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Cystic fibrosis
Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug
October 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
October 23, 2025
 · 
3 min read
 · 
Tristan Manalac
Museum island on Spree river and Alexanderplatz TV tower in center of Berlin, Germany
Cancer
ADC, Bispecifics and Kinase Blockers Steal the Spotlight at ESMO 2025 in Berlin
October 22, 2025
 · 
4 min read
 · 
Tristan Manalac